ZyGEM Incorporates its DNA Extraction Technology into RUBICON’s Research and Diagnostic Products
News May 29, 2009
ZyGEM Corp. Ltd. has announced that it has entered into an agreement with Rubicon Genomics, Inc. to incorporate ZyGEM’s advanced enzymatic nucleic acid extraction technology into Rubicon’s pre-analytical platform products designed to improve the performance of DNA and RNA analytical instruments.
The agreement, which will initially focus on diagnostic single-cell whole genome amplification kits, has the potential to be expanded to include products for broader research and diagnostic applications.
ZyGEM’s technology uses a proprietary thermophilic enzyme to extract DNA from samples using a single closed-tube system. ZyGEM’s approach significantly reduces the time and cost of DNA extractions while simplifying laboratory workflow, minimizing error, reducing the risk of contamination, ensuring sample integrity and facilitating extractions from trace samples. It is easily adaptable for use with virtually all off-the-shelf laboratory automation systems.
The technology can be specifically formulated for use with a wide range of different sample types without the need for further purification. ZyGEM’s technology has been validated for use in highly regulated applications including forensic analysis.
“ZyGEM’s unique temperature-controlled DNA extraction technology provides important advantages for the analysis of DNA and RNA, and we are delighted to partner with Rubicon in our drive to make our technology widely available for diverse research and clinical applications,” said Paul Kinnon, CEO of ZyGEM.
“This new agreement for private-label DNA extraction products is the most recent in a series of ZyGEM collaborations for our versatile technology, and we look forward to a productive and expanding relationship with Rubicon, an emerging leader in pre-analytical amplification of clinical samples.”
Rubicon will soon launch its PicoPlex™ kits, which integrate ZyGEM’s proprietary DNA extraction technology into a novel method to amplify single genomes with accuracy and reproducibility. This product targets the pre-implantation genetic diagnostics and cancer diagnostics markets, which require reproducible amplification to profile patient genotypes, karyotypes and mutations.
PicoPlex enables reference labs to begin qPCR, microarray or sequencing analysis less than three hours after collecting patient cells. The company claims to have designed the PicoPlex to be faster, accurate and more reproducible than other methods for single cell DNA amplification.
“We believe that the growing customer base for our pre-analytical solutions for DNA and RNA analysis will benefit from access to the unique nucleic acid extraction technology developed by ZyGEM,” said James Koziarz, acting president and CEO of Rubicon. “We have greatly improved the clinical performance of whole genome amplification by incorporating ZyGEM technology and other proprietary reagents into our kits, which have been shown to increase the sensitivity, specificity and robustness of most research and diagnostic analytical platforms.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE